177 related articles for article (PubMed ID: 37908231)
1. AVEN: a novel oncogenic biomarker with prognostic significance and implications of AVEN-associated immunophenotypes in lung adenocarcinoma.
Fan D; Yang M; Lee HJ; Lee JH; Kim HS
Front Mol Biosci; 2023; 10():1265359. PubMed ID: 37908231
[No Abstract] [Full Text] [Related]
2. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma.
Ma C; Kang W; Yu L; Yang Z; Ding T
Front Oncol; 2020; 10():590006. PubMed ID: 33363020
[TBL] [Abstract][Full Text] [Related]
3. Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma.
Xu ZY; Zhao M; Chen W; Li K; Qin F; Xiang WW; Sun Y; Wei J; Yuan LQ; Li SK; Lin SH
PeerJ; 2020; 8():e9530. PubMed ID: 32775050
[TBL] [Abstract][Full Text] [Related]
4. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
PeerJ; 2023; 11():e16166. PubMed ID: 37790630
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
Front Genet; 2022; 13():1017866. PubMed ID: 36699466
[No Abstract] [Full Text] [Related]
6. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
8. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
10. DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma.
Wu YJ; Nai AT; He GC; Xiao F; Li ZM; Tang SY; Liu YP; Ai XH
World J Surg Oncol; 2021 Sep; 19(1):274. PubMed ID: 34517904
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
Chen J; Zhou R
PeerJ; 2021; 9():e10628. PubMed ID: 33520448
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of resistance mechanisms to EGFR-TKIs and establishment and validation of prognostic model.
Yang Z; Li H; Dong T; Li G; Chen D; Li S; Wang Y; Pan Y; Lu T; Yang G; Zhang G; Cheng P; Wang X
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13773-13792. PubMed ID: 37532906
[TBL] [Abstract][Full Text] [Related]
15. Identification of CDK2-Related Immune Forecast Model and ceRNA in Lung Adenocarcinoma, a Pan-Cancer Analysis.
Liu TT; Li R; Huo C; Li JP; Yao J; Ji XL; Qu YQ
Front Cell Dev Biol; 2021; 9():682002. PubMed ID: 34409029
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
17. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates.
Wei Q; Miao T; Zhang P; Jiang B; Yan H
Front Genet; 2022; 13():984575. PubMed ID: 36159963
[No Abstract] [Full Text] [Related]
19. Identification of a three-gene expression signature and construction of a prognostic nomogram predicting overall survival in lung adenocarcinoma based on TCGA and GEO databases.
Zhou Y; Gao S; Yang R; Du C; Wang Y; Wu Y
Transl Lung Cancer Res; 2022 Jul; 11(7):1479-1496. PubMed ID: 35958325
[TBL] [Abstract][Full Text] [Related]
20. Identification of
Bian T; Zhang W; Wang F; Chu X; Pan X; Ruan J; Yu S; Liu L; Sun H; Qiu H; Li Y; Tang J; Zhao X; Zhang H
Comb Chem High Throughput Screen; 2023; 26(14):2452-2468. PubMed ID: 37038295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
